Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Acumen Pharmaceuticals, Inc.ABOS · Entity 6281 | Chief Regulatory Officer | January 16, 2026 | January 21, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Acumen Pharmaceuticals, Inc.
Report date January 16, 2026 · Filed January 21, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 92,303 |
Reported balance
After 2026-01-16 transaction · row 1
1 source rowRow 1 · 2026-01-16 · Grant · Acquired 84,600 · Balance 92,303 F1: Represents a restricted stock unit ("RSU") award. Each RSU represents a contingent right to receive one share of the Issuer's Common Stock. The RSUs will vest in three equal annual installments commencing one year after the grant date, subject to the Reporting Person's continuous service through each such vesting date. |
| Employee Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $1.89 · Expires 2036-01-16 | Direct | 126,900 |
Reported balance
After 2026-01-16 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2026-01-16 · Grant · Acquired 126,900 · Balance 126,900 F2: The shares subject to the option will vest in 48 equal monthly installments such that the option is fully vested on the fourth anniversary of the date of grant, subject to the Reporting Person's continuous service through each such vesting date. |
Filing footnotes · ownership attribution and instrument terms
F1: Represents a restricted stock unit ("RSU") award. Each RSU represents a contingent right to receive one share of the Issuer's Common Stock. The RSUs will vest in three equal annual installments commencing one year after the grant date, subject to the Reporting Person's continuous service through each such vesting date.
F2: The shares subject to the option will vest in 48 equal monthly installments such that the option is fully vested on the fourth anniversary of the date of grant, subject to the Reporting Person's continuous service through each such vesting date.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| January 16, 2026 Filed Jan 21, 2026 18:29 UTC | Acumen Pharmaceuticals, Inc. ABOS · Entity 6281 | GrantEmployee Stock Option (right to buy) · Derivative | 126,900 | $0.00 Strike: $1.89 | $0.00 |
DisclosureSEC source: 0001628280-26-002957 · wk-form4_1769038189.xml · derivative · entry 2 Schacterle Amy · CIK 0002042021 · Chief Regulatory Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 126,900 Underlying: Common Stock · 126,900 shares Expires 2036-01-16 F2 · derivative.exercise_date: The shares subject to the option will vest in 48 equal monthly installments such that the option is fully vested on the fourth anniversary of the date of grant, subject to the Reporting Person's continuous service through each such vesting date. Read SEC document |
| January 16, 2026 Filed Jan 21, 2026 18:29 UTC | Acumen Pharmaceuticals, Inc. ABOS · Entity 6281 | GrantCommon Stock | 84,600 | $0.00 | $0.00 |
DisclosureSEC source: 0001628280-26-002957 · wk-form4_1769038189.xml · nonDerivative · entry 1 Schacterle Amy · CIK 0002042021 · Chief Regulatory Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 92,303 F1 · shares: Represents a restricted stock unit ("RSU") award. Each RSU represents a contingent right to receive one share of the Issuer's Common Stock. The RSUs will vest in three equal annual installments commencing one year after the grant date, subject to the Reporting Person's continuous service through each such vesting date. Read SEC document |
| January 07, 2026 Filed Jan 9, 2026 16:38 UTC | Acumen Pharmaceuticals, Inc. ABOS · Entity 6281 | SaleCommon Stock | 1,097 | $1.98 | $2,176.23 |
DisclosureSEC source: 0001628280-26-001633 · wk-form4_1767994720.xml · nonDerivative · entry 1 Schacterle Amy · CIK 0002042021 · Chief Regulatory Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 7,703 F1 · shares: Represents the number of shares sold by the Reporting Person through an automatic "sell to cover" transaction to satisfy tax withholding obligations in connection with the vesting of restricted stock units pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on September 30, 2025. F2 · price: The price reported is a weighted average sales price. The shares were sold in multiple transactions at prices ranging from $1.9550 to $2.0100. Upon request, the Reporting Person will provide to the staff of the Securities and Exchange Commission, the Issuer, or any security holder of the Issuer, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| January 06, 2025 Filed Jan 7, 2025 20:02 UTC | Acumen Pharmaceuticals, Inc. ABOS · Entity 6281 | GrantEmployee Stock Option (right to buy) · Derivative | 13,200 | $0.00 Strike: $1.85 | $0.00 |
DisclosureSEC source: 0001576885-25-000019 · wk-form4_1736298170.xml · derivative · entry 2 Schacterle Amy · CIK 0002042021 · Chief Regulatory Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 13,200 Underlying: Common Stock · 13,200 shares Expires 2035-01-06 F2 · derivative.exercise_date: The shares subject to the option will vest in 48 equal monthly installments such that the option is fully vested on the fourth anniversary of the date of grant, subject to the Reporting Person's continuous service through each such vesting date. Read SEC document |
| January 06, 2025 Filed Jan 7, 2025 20:02 UTC | Acumen Pharmaceuticals, Inc. ABOS · Entity 6281 | GrantCommon Stock | 8,800 | $0.00 | $0.00 |
DisclosureSEC source: 0001576885-25-000019 · wk-form4_1736298170.xml · nonDerivative · entry 1 Schacterle Amy · CIK 0002042021 · Chief Regulatory Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 8,800 F1 · shares: Represents a restricted stock unit ("RSU") award. Each RSU represents a contingent right to receive one share of the Issuer's Common Stock. The RSUs will vest in three equal annual installments commencing one year after the grant date, subject to the Reporting Person's continuous service through each such vesting date. Read SEC document |
| November 05, 2024 Filed Nov 6, 2024 17:27 UTC | Acumen Pharmaceuticals, Inc. ABOS · Entity 6281 | GrantEmployee Stock Option (right to buy) · Derivative | 340,000 | $0.00 Strike: $2.95 | $0.00 |
DisclosureSEC source: 0000950170-24-122484 · ownership.xml · derivative · entry 1 Schacterle Amy · CIK 0002042021 · Chief Regulatory Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 340,000 Underlying: Common Stock · 340,000 shares Expires 2034-11-05 F1 · derivative.exercise_date: Twenty-five percent (25%) of the shares subject to the option shall vest and become exercisable on November 5, 2025, and one thirty-sixth (1/36th) of the remaining shares subject to the option shall vest and become exercisable each month thereafter, subject to Reporting Person continuing to provide service through each such date. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.